Dustin A Heldman1, Denzil A Harris2,3, Timothy Felong3, Kelly L Andrzejewski4,5, E Ray Dorsey3,4, Joseph P Giuffrida1, Barry Goldberg1, Michelle A Burack4. 1. Great Lakes NeuroTechnologies, Cleveland, OH, USA. 2. School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, USA. 3. Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY, USA. 4. Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. 5. Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Abstract
BACKGROUND: Parkinson's disease (PD) motor symptoms can fluctuate and may not be accurately reflected during a clinical evaluation. In addition, access to movement disorder specialists is limited for many with PD. The objective was to assess the impact of motion sensor-based telehealth diagnostics on PD clinical care and management. METHODS: Eighteen adults with PD were randomized to control or experimental groups. All participants were instructed to use a motion sensor-based monitoring system at home one day per week, for seven months. The system included a finger-worn motion sensor and tablet-based software interface that guided patients through tasks to quantify tremor, bradykinesia, and dyskinesia. Data were processed into motor symptom severity reports, which were reviewed by a movement disorders neurologist for experimental group participants. After three months and six months, control group participants visited the clinic for a routine appointment, while experimental group participants had a videoconference or phone call instead. RESULTS: Home based assessments were completed with median compliance of 95.7%. For a subset of participants, the neurologist successfully used information in the reports such as quantified response to treatment or progression over time to make therapy adjustments. Changes in clinical characteristics from study start to end were not significantly different between groups. DISCUSSION: Individuals with PD were able and willing to use remote monitoring technology. Patient management aided by telehealth diagnostics provided comparable outcomes to standard care. Telehealth technologies combined with wearable sensors have the potential to improve care for disparate PD populations or those unable to travel.
BACKGROUND: Parkinson's disease (PD) motor symptoms can fluctuate and may not be accurately reflected during a clinical evaluation. In addition, access to movement disorder specialists is limited for many with PD. The objective was to assess the impact of motion sensor-based telehealth diagnostics on PD clinical care and management. METHODS: Eighteen adults with PD were randomized to control or experimental groups. All participants were instructed to use a motion sensor-based monitoring system at home one day per week, for seven months. The system included a finger-worn motion sensor and tablet-based software interface that guided patients through tasks to quantify tremor, bradykinesia, and dyskinesia. Data were processed into motor symptom severity reports, which were reviewed by a movement disorders neurologist for experimental group participants. After three months and six months, control group participants visited the clinic for a routine appointment, while experimental group participants had a videoconference or phone call instead. RESULTS: Home based assessments were completed with median compliance of 95.7%. For a subset of participants, the neurologist successfully used information in the reports such as quantified response to treatment or progression over time to make therapy adjustments. Changes in clinical characteristics from study start to end were not significantly different between groups. DISCUSSION: Individuals with PD were able and willing to use remote monitoring technology. Patient management aided by telehealth diagnostics provided comparable outcomes to standard care. Telehealth technologies combined with wearable sensors have the potential to improve care for disparate PD populations or those unable to travel.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: C L Pulliam; S R Eichenseer; C G Goetz; O Waln; C B Hunter; J Jankovic; D E Vaillancourt; J P Giuffrida; D A Heldman Journal: Parkinsonism Relat Disord Date: 2013-09-19 Impact factor: 4.891
Authors: S Arora; V Venkataraman; A Zhan; S Donohue; K M Biglan; E R Dorsey; M A Little Journal: Parkinsonism Relat Disord Date: 2015-03-07 Impact factor: 4.891
Authors: Dustin A Heldman; Alberto J Espay; Peter A LeWitt; Joseph P Giuffrida Journal: Parkinsonism Relat Disord Date: 2014-03-05 Impact factor: 4.891
Authors: James M Fisher; Nils Y Hammerla; Lynn Rochester; Peter Andras; Richard W Walker Journal: Telemed J E Health Date: 2015-07-17 Impact factor: 3.536
Authors: Graeme Mattison; Oliver Canfell; Doug Forrester; Chelsea Dobbins; Daniel Smith; Juha Töyräs; Clair Sullivan Journal: J Med Internet Res Date: 2022-07-01 Impact factor: 7.076
Authors: Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton Journal: Alzheimers Dement Date: 2020-01-06 Impact factor: 21.566
Authors: Christopher Kovalchick; Rhea Sirkar; Oliver B Regele; Lampros C Kourtis; Marie Schiller; Howard Wolpert; Rhett G Alden; Graham B Jones; Justin M Wright Journal: J Clin Transl Sci Date: 2017-12